Department of Obstetrics and Gynaecology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR.
Shenzhen Youshare Biotechnology Co. Ltd, Shenzhen, China.
Am J Reprod Immunol. 2019 Feb;81(2):e13077. doi: 10.1111/aji.13077. Epub 2019 Jan 23.
Intrauterine infusion of human chorionic gonadotropin (IUI-hCG) has been proposed to improve the outcome of in vitro fertilization-embryo transfer (IVF-ET), since it plays a critical role in synchronizing endometrial and fetal development. As the early mediator from embryo, hCG promotes the decidualization, angiogenesis, maternal immune tolerance, and trophoblast invasion, favoring successful implantation of embryo. Although multiple clinical trials have been conducted to verify the efficacy of IUI-hCG on IVF-ET outcome in recent years, the findings remained controversial. The difference in study design and population might be the cause to the different consequences after administration of hCG. More importantly, the endometrial receptivity, which might affect the efficacy of IUI-hCG, has not been assessed in women receiving this intervention. Selecting the right population suitable for IUI-hCG based on known etiology would be crucial in enhancing its efficacy and minimize any possible complications. Investigation of optimal indications for IUI-hCG should be highlighted in the future.
宫腔内注射人绒毛膜促性腺激素(IUI-hCG)已被提议用于改善体外受精-胚胎移植(IVF-ET)的结局,因为它在同步子宫内膜和胎儿发育方面起着关键作用。作为胚胎的早期介质,hCG 促进蜕膜化、血管生成、母体免疫耐受和滋养细胞浸润,有利于胚胎的成功着床。尽管近年来已经进行了多项临床试验来验证 IUI-hCG 对 IVF-ET 结局的疗效,但研究结果仍存在争议。研究设计和人群的差异可能是 hCG 给药后产生不同结果的原因。更重要的是,接受这种干预的女性的子宫内膜容受性可能会影响 IUI-hCG 的疗效,但尚未对此进行评估。根据已知病因选择适合 IUI-hCG 的合适人群对于提高其疗效和最小化任何可能的并发症至关重要。未来应强调研究 IUI-hCG 的最佳适应证。